Wang H, Abbas KM, Abbasifard M, Abbasi-Kangevari M, Abbastabar H, Abd-Allah F, et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1160–203.

Article  Google Scholar 

Torres TS, Harrison LJ, La Rosa AM, Cardoso SW, Zheng L, Ngongondo M, et al. Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS. 2018;32(5):583–93.

Article  PubMed  Google Scholar 

Trickey A, Sabin CA, Burkholder G, Crane H, d’Arminio Monforte A, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295-307.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu JCY, Leung JM, Ngan DA, Nashta NF, Guillemi S, Harris M, et al. Absolute leukocyte telomere length in HIV-infected and uninfected individuals: evidence of accelerated cell senescence in HIV-associated chronic obstructive pulmonary disease. Morris A, organizador. PLoS ONE. 2015;10(4): e0124426.

Article  PubMed  PubMed Central  Google Scholar 

Rodés B, Cadiñanos J, Esteban-Cantos A, Rodríguez-Centeno J, Arribas JR. Ageing with HIV: Challenges and biomarkers. Biomedicine. 2022;77: 103896.

Google Scholar 

Zanet DL, Thorne A, Singer J, Maan EJ, Sattha B, Le Campion A, et al. Association between short leukocyte telomere length and HIV infection in a cohort study: no evidence of a relationship with antiretroviral therapy. Clin Infect Dis. 2014;58(9):1322–32.

Article  PubMed  Google Scholar 

Mann SC, Castillo-Mancilla JR. HIV, aging, and adherence: an update and future directions. Curr Opin HIV AIDS. 2020;15(2):134–41.

Article  PubMed  Google Scholar 

Milic J, Russwurm M, Cerezales Calvino A, Brañas F, Sánchez-Conde M, Guaraldi G. European cohorts of older HIV adults: POPPY, AGEhIV, GEPPO COBRA and FUNCFRAIL. Eur Geriatr Med. 2019;10(2):247–57.

Article  PubMed  Google Scholar 

Andres TM, McGrane T, McEvoy MD, Allen BFS. Geriatric pharmacology. Anesthesiol Clin. 2019;37(3):475–92.

Article  PubMed  Google Scholar 

Mukhtar O, Jackson SH. Drug therapies in older adults (part 1). Clin Med. 2015;15(1):47–53.

Article  Google Scholar 

Stillhart C, Vučićević K, Augustijns P, Basit AW, Batchelor H, Flanagan TR, et al. Impact of gastrointestinal physiology on drug absorption in special populations––An UNGAP review. Eur J Pharm Sci. 2020;147: 105280.

Article  CAS  PubMed  Google Scholar 

Da Silva RPN, Marins LMS, Guaraldo L, Luz PM, Cardoso SW, Moreira RI, et al. Pharmacotherapeutic profile, polypharmacy and its associated factors in a cohort of people living with HIV in Brazil. AIDS Res Ther. 2023;20(1):57.

Article  PubMed  PubMed Central  Google Scholar 

Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol. 2019;12(7):643–59.

Article  CAS  PubMed  Google Scholar 

Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233.

Article  PubMed  Google Scholar 

Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013;9(5):573–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

GlaxoSmithKline. Ziagen (abacavir)[package insert]. 2020.

Bristol-Myers Squibb Company. Reyataz (atazanavir) [package insert]. 2023.

XLCare Pharmaceuticals Inc. Efavirenz [package insert]. 2023.

Gilead Sciences, Inc. Emtriva (emtricitabine) [package insert]. 2021.

AbbVie Inc. Kaletra (lopinavir/ritonavir) [package insert]. 2023.

Gilead Sciences, Inc. Viread (tenofovir disoproxil fumarate) [package insert]. 2021.

Camber Pharmaceuticals, Inc. Zidovudine [package insert]. 2023.

Toledo T, Castro T, Oliveira VG, Veloso VG, Grinsztejn B, Cardoso SW, et al. Pharmacokinetics of antiretroviral drugs in older people living with HIV: a systematic review. Clin Pharmacokinet. 2023;62(9):1219–30.

Article  PubMed  Google Scholar 

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:7647.

Article  Google Scholar 

NIH. HIVinfo. 2023 [accessed 3 July 2024]. FDA-Approved HIV Medicines. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines

Fontela C, Castilla J, Juanbeltz R, Martínez-Baz I, Rivero M, O’Leary A, et al. Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016. Postgrad Med. 2018;130(3):317–24.

Article  PubMed  Google Scholar 

Maciel RA, Klück HM, Durand M, Sprinz E. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: A cross-sectional study. Int J Infect Dis. 2018;70:30–5.

Article  PubMed  Google Scholar 

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, et al. A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs. Clin Pharmacokinet. 2019;58(6):747–66.

Article  CAS  PubMed  Google Scholar 

Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 2006;26(4):511–4.

Article  CAS  PubMed  Google Scholar 

van Dam PM, van Geffen MW, Havenith TR, Posthouwer D. Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man. Antivir Ther. 2018;23(6):549–52.

Article  PubMed  Google Scholar 

Chittick GE, Gillotin C, McDowell JA, Lou Y, Edwards KD, Prince WT, et al. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 1999;19(8):932–42.

Article  CAS  PubMed  Google Scholar 

Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S, et al. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 1999;43(3):603–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Izzedine H, Launay-Vacher V, Aymard G, Legrand M, Deray G. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron. 2001;89(1):62–7.

Article  CAS  PubMed  Google Scholar 

Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob Agents Chemother. 1992;36(8):1773–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallicano KD, Tobe S, Sahai J, McGilveray IJ, Cameron DW, Kriger F, et al. Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). J Acquir Immune Defic Syndr. 1992;5(3):242–50.

Article  CAS  PubMed  Google Scholar 

Moore KH, Raasch RH, Brouwer KL, Opheim K, Cheeseman SH, Eyster E, et al. Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrob Agents Chemother. 1995;39(12):2732–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramachandran G, Hemanthkumar AK, Kumaraswami V, Swaminathan S. A simple and rapid liquid chromatography method for simultaneous determination of zidovudine and nevirapine in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;843(2):339–44.

Article  CAS  PubMed  Google Scholar 

Gallicano K, Sahai J, Swick L, Seguin I, Pakuts A, Cameron DW. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infect Dis Off Publ Infect Dis Soc Am. 1995;21(4):1008–11.

Article  CAS  Google Scholar 

Hayashi S, Jayesekera D, Jayewardene A, Shah A, Thevanayagam L, Aweeka F. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients. J Clin Pharmacol. 1999;39(10):1085–93.